Phaseline

Targets › PDE1

PDE1: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Neurology; next expected readout Nov 2026.

Open in Phaseline: the race on PDE1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Tanta UniversityVinpocetine
Phosphodiesterase-1 (PDE1) inhibitor that increases dopamine levels and protects dopaminer
PDE1Phase 2Parkinson DiseaseNov 2026

Conditions

Parkinson Disease (1)

Modalities

small molecule (1)

Companies

Tanta University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.